TauRx Attempts Anti-Tau Comeback But Keeps Data Under Wraps

Following 2016 Alzheimer’s Fail

01 Jun 2022

• By Ayisha Sharma

The firm has revealed its anti-tau candidate showed promise in a late-stage Alzheimer’s study several years after a disappointing failure, but data are yet to be announced in full.

Alzheimer's Is Caused By The Abnormal Build-Up Of Protein In Brain Cells • Source: Alamy

TauRx Therapeutics Ltd.’s tau aggregation inhibitor candidate for Alzheimer’s has improved cognitive and functional decline rates according to initial data from a late-stage trial but the lack of numbers leaves room for skepticism given the product’s past.

The Singaporean biotech claimed patients treated with hydromethylthionine mesylate (HMTM) saw decline at a rate substantially lower than is typical in Alzheimer’s disease during the Phase III LUCIDITY trial, adding...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

In Brief: Nicox Extends Cash Runway As Kowa Advances NCX 470 In Japan

29 May 2025

• By Sushmita Panda

Eye drug is already in Phase III trials elsewhere, with results due in Q3. Nicox could earn up to a further €24.5m in milestones and royalties from Kowa alliance.

GSK’s Bet On Spero’s Oral cUTI Antibiotic Poised To Pay Off With New Phase III Data

28 May 2025

• By Joseph Haas

Spero and partner GSK have Phase III non-inferiority data to support approval of tebipenem as the first oral antibiotic for complicated urinary tract infections.